Conjugation of Cetuximab - Puromycin and Its Target-Specific Effect on Triple Negative Breast Cancer Cell Lines.
Diah PuspitasariSeptelias Inawati WanandiMohamad SadikinPublished in: Asian Pacific journal of cancer prevention : APJCP (2022)
Synthesized conjugate showed its target-specific effect in TNBC and improved the efficacy of Cetuximab on TNBC. In the future, this conjugate can be a potential anticancer therapy in treating triple-negative breast cancer.